Significant
unprotected LM disease constitutes approximately 5-10% of patients undergoing
coronary angiography. Randomized clinical trials (RCTs) have demonstrated a
higher rate of repeat revascularization after percutaneous coronaryintervention (PCI) compared with coronary artery bypass grafting (CABG), but a
lower incidence of cerebrovascular events; no differences were reported in
overall major adverse cardiovascular events (MACEs).
Although CABG has been the
gold standard therapy for LM disease until recently, significant innovation in
stent technology, revascularization techniques and antithrombotic therapies
make PCI feasible. Treatment of ostial and mid-shaft has shown excellent
outcomes with minimal mortality and long-term complications compared with
distal LM bifurcations. Lack of RCTs addressing LM bifurcation has led to
uncertainties regarding optimal stenting strategy. Read more>>>>>>>>>>>
No comments:
Post a Comment